Literature DB >> 25343126

Radiographic characteristics of the hand and cervical spine in fibrodysplasia ossificans progressiva.

Kenichi Mishima1, Hiroshi Kitoh2, Nobuhiko Haga3, Yasuharu Nakashima3, Junji Kamizono3, Takenobu Katagiri3, Takafumi Susami3, Masaki Matsushita1, Naoki Ishiguro1.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a disabling heritable disorder of connective tissue characterized by progressive heterotopic ossification in various extraskeletal sites. Early correct diagnosis of FOP is important to prevent additional iatrogenic harm or trauma. Congenital malformation of the great toes is a well-known diagnostic clue, but some patients show normal-appearing great toes. The thumb shortening and cervical spine abnormalities are other skeletal features often observed in FOP. This study aimed to address the quantitative assessment of these features in a cohort of patients with FOP, which potentially helps early diagnosis of FOP. Radiographs of the hand and cervical spine were retrospectively analyzed from a total of 18 FOP patients (9 males and 9 females) with an average age of 13.9 years (range 0.7-39.3 years). The elevated ratio of the second metacarpal bone to the distal phalanx of the thumb (> +1SD) was a consistent finding irrespective of the patient's age and gender. Infant FOP patients, in addition, exhibited an extremely high ratio of the second metacarpal bone to the first metacarpal bone (> +3SD). The height/depth ratio of the C5 vertebra increased in patients over 4 years of age (> +2SD). Additionally, the ratio of (height+depth) of the C5 spinous process to the C5 vertebral depth was markedly elevated in young patients (> +2SD). We quantitatively demonstrated the hand and cervical spine characteristics of FOP. These findings, which can be seen from early infancy, could be useful for early diagnosis of FOP even in patients without great toe abnormalities.

Entities:  

Keywords:  Fibrodysplasia ossificans progressiva; early diagnosis; radiographic characteristics

Year:  2014        PMID: 25343126      PMCID: PMC4204539          DOI: 10.5582/irdr.2014.01009

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  17 in total

1.  Tailored Hox gene transcription and the making of the thumb.

Authors:  Jacqueline Deschamps
Journal:  Genes Dev       Date:  2008-02-01       Impact factor: 11.361

2.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

3.  Deformity of the great toe in fibrodysplasia ossificans progressiva.

Authors:  Yasuharu Nakashima; Nobuhiko Haga; Hiroshi Kitoh; Junji Kamizono; Koji Tozawa; Takenobu Katagiri; Takafumi Susami; Jun-ichi Fukushi; Yukihide Iwamoto
Journal:  J Orthop Sci       Date:  2010-11-30       Impact factor: 1.601

Review 4.  Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

5.  Reference values for radiological evaluation of cervical vertebral body shape and spinal canal.

Authors:  V M Remes; M T Heinänen; J S Kinnunen; E J Marttinen
Journal:  Pediatr Radiol       Date:  2000-03

6.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

Review 7.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

Review 8.  Fibrodysplasia ossificans progressiva: clinical and genetic aspects.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Orphanet J Rare Dis       Date:  2011-12-01       Impact factor: 4.123

9.  The role of bone morphogenetic proteins in vertebral development.

Authors:  A H Monsoro-Burq; D Duprez; Y Watanabe; M Bontoux; C Vincent; P Brickell; N Le Douarin
Journal:  Development       Date:  1996-11       Impact factor: 6.868

10.  Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial.

Authors:  Hiroshi Kitoh; Masataka Achiwa; Hiroshi Kaneko; Kenichi Mishima; Masaki Matsushita; Izumi Kadono; John D Horowitz; Benedetta C Sallustio; Kinji Ohno; Naoki Ishiguro
Journal:  Orphanet J Rare Dis       Date:  2013-10-16       Impact factor: 4.123

View more
  3 in total

1.  Characteristic calcaneal ossification: an additional early radiographic finding in infants with fibrodysplasia ossificans progressiva.

Authors:  Sachi Hasegawa; Teresa Victoria; Hülya Kayserili; Elaine Zackai; Gen Nishimura; Nobuhiko Haga; Yasuharu Nakashima; Osamu Miyazaki; Hiroshi Kitoh
Journal:  Pediatr Radiol       Date:  2016-08-04

2.  Clinical and molecular characterisation of two siblings with fibrodysplasia ossificans progressiva, from the Colombian Pacific coast (South America).

Authors:  Harry Pachajoa; Andres Felipe Ramirez Botero
Journal:  BMJ Case Rep       Date:  2015-06-08

Review 3.  BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).

Authors:  Oscar Will Towler; Eileen M Shore
Journal:  Dev Dyn       Date:  2021-06-26       Impact factor: 2.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.